Zobrazeno 1 - 10
of 29
pro vyhledávání: '"B. J. Foster"'
Autor:
B. J. Foster, M. L. Roberson
Publikováno v:
Essential Readings in Light Metals ISBN: 9783319485744
Essential Readings in Light Metals: Alumina and Bauxite, Volume 1
Essential Readings in Light Metals: Alumina and Bauxite, Volume 1
Since the late 1970’s, extensive testing has been conducted at Gramercy to remove high molecular weight organic compounds (humates) from Bayer process liquors. Early research work tested the removal of humates using the Giulini process (Dolime) , a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477416ad1a064c522e79e87d74427b54
https://doi.org/10.1007/978-3-319-48176-0_40
https://doi.org/10.1007/978-3-319-48176-0_40
Publikováno v:
British Journal of Cancer
The dose limiting toxicities of the short infusion trial of the dacarbazine analog, CB10-277, were nausea and vomiting which appeared to be related to the peak plasma level of the parent drug. In addition, based on mouse studies, these dose limiting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aa436678699df361cfce9312f3878a2
https://doi.org/10.1038/bjc.1993.67
https://doi.org/10.1038/bjc.1993.67
Autor:
B J Foster, Al Harris, Alan Hilary Calvert, David R. Newell, L A Gumbrell, P M Goodard, J Carmichael, M Jones
Publikováno v:
British Journal of Cancer
Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb1a994529d5901f085dc38ffcec728a
http://europepmc.org/articles/PMC1968184
http://europepmc.org/articles/PMC1968184
Autor:
L. Gumbrell, K. E. Jenns, Alan Hilary Calvert, S. B. Kaye, Martin A. Graham, David R. Newell, B. J. Foster
Publikováno v:
European Journal of Cancer. 28:463-469
The development of new drugs in early clinical trials is currently based upon the results of preclinical antitumour and toxicity studies in animals. More recently, the use of preclinical pharmacokinetic information in mice has been proposed to also p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb7700801c120badc30733e91b3dcf9
https://doi.org/10.1016/s0959-8049(05)80077-2
https://doi.org/10.1016/s0959-8049(05)80077-2
Autor:
S, Prakash, B J, Foster, M, Meyer, A, Wozniak, L K, Heilbrun, L, Flaherty, M, Zalupski, L, Radulovic, M, Valdivieso, P M, LoRusso
Publikováno v:
Investigational new drugs. 19(1)
CI-994 (N-acetyl dinaline, PD 123654) is a novel oral agent active in a broad variety of murine and human tumor xenografts. While cytotoxic in the Brown Norway (BN) rat leukemia model, growth inhibition in other murine and human tumor xenografts is p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e2d1a975937dc212af47779bc38b8b85
https://pubmed.ncbi.nlm.nih.gov/11291827
https://pubmed.ncbi.nlm.nih.gov/11291827
Autor:
P M, LoRusso, B J, Foster, A, Wozniak, L K, Heilbrun, J I, McCormick, P E, Ruble, M A, Graham, J, Purvis, J, Rake, M, Drozd, G F, Lockwood, T H, Corbett
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(8)
SR233377 is a novel thioxanthenone analogue that demonstrated solid tumor selectivity in vitro with activity confirmed in vivo against several murine tumors including those of colon, pancreas, and mammary origin. Its primary preclinical dose-limiting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e44301546982d7214898850eff7d52f2
https://pubmed.ncbi.nlm.nih.gov/10955788
https://pubmed.ncbi.nlm.nih.gov/10955788
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(11)
Two new thioxanthenones, 183577 and 232759, have rekindled interest in the development of representatives from this class of structures as useful anticancer agents. Although the mechanism of action is unknown, both compounds demonstrated a similar sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::532f6ea67b62370bf22feffdb1d2016b
https://pubmed.ncbi.nlm.nih.gov/9815596
https://pubmed.ncbi.nlm.nih.gov/9815596
Publikováno v:
Investigational new drugs. 15(3)
CI-994, a substituted benzamide derivative, is a compound that showed solid tumor selectivity for a variety of solid tumor models compared to L1210 leukemia. Due to its lack of aqueous solubility, it requires oral administration. Female B6D2F1 mice w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::46f6fd9be888a3ba4c9b28b811d140da
https://pubmed.ncbi.nlm.nih.gov/9387041
https://pubmed.ncbi.nlm.nih.gov/9387041
Autor:
B J, Foster, B, Gipe
Publikováno v:
Costquality quarterly journal : CQ. 3(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15df1291ae4611904eacbcbe904bbdd4
https://pubmed.ncbi.nlm.nih.gov/10167032
https://pubmed.ncbi.nlm.nih.gov/10167032
Autor:
P, LoRusso, B J, Foster, E, Poplin, J, McCormick, M, Kraut, L, Flaherty, L K, Heilbrun, M, Valdivieso, L, Baker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 1(12)
The pyrazoloacridine (PZA) analogue NSC366140 (PD115934) entered clinical trial based on unique preclinical characteristics including solid tumor selectivity in vitro, marked antitumor activity in vivo against murine solid tumors, selectivity against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::96a9b1c06752f3e505f5b9b76eaeec48
https://pubmed.ncbi.nlm.nih.gov/9815948
https://pubmed.ncbi.nlm.nih.gov/9815948